



12. A compound represented by the formula



5 or a pharmaceutically acceptable salt thereof.


13. A compound represented by the formula



or a pharmaceutically acceptable salt thereof.


10

14. A compound represented by the formula




or a pharmaceutically acceptable salt thereof.

15 15. A compound represented by the formula



or a pharmaceutically acceptable salt thereof.


16. A compound represented by the formula



5

or a pharmaceutically acceptable salt thereof.

17. A compound represented by the formula



10 or a pharmaceutically acceptable salt thereof.

1812. A pharmaceutical composition comprising the compound according to any one of claims 1 to 1711 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

1913. An anti-HIV agent comprising the compound according to any one of claims 1 to 1711 or a pharmaceutically acceptable salt thereof, as an active ingredient.

2014. An HIV integrase inhibitor comprising the compound according to any one of claims 1 to 1711 or a pharmaceutically acceptable salt thereof, as an active ingredient.

2115. An anti-HIV agent comprising the compound according to any one of claims 1 to 1711 or a pharmaceutically acceptable salt thereof, in combination with one or more other kinds of anti-HIV active substances.

~~16. Use of the compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, for the production of an anti-HIV agent.~~

~~17. Use of the compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, for the production of an HIV integrase inhibitor.~~

~~1822. Use of a compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament A method for the prophylaxis or treatment of an HIV infection in a mammal, comprising administering an effective amount of the compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, to the mammal.~~

1923. ~~The method-use~~ according to claim 1822, ~~further comprising administering~~ wherein the medicament is to be administered in combination with an effective amount of one or more other kinds of anti-HIV active substances to the mammal.

5

2024. Use of a compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament ~~A method for inhibiting HIV integrase in a mammal, comprising administering an effective amount of the~~
10 ~~compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, to the mammal.~~